Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Cash & Current Investments (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Cash & Current Investments for 3 consecutive years, with $99.6 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Cash & Current Investments fell 20.75% year-over-year to $99.6 million, compared with a TTM value of $99.6 million through Sep 2024, down 20.75%, and an annual FY2023 reading of $66.8 million, up 51.03% over the prior year.
  • Cash & Current Investments was $99.6 million for Q3 2024 at Oramed Pharmaceuticals, up from $86.5 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $125.6 million in Q3 2023 and bottomed at $7.1 million in Q2 2023.
  • Average Cash & Current Investments over 3 years is $60.3 million, with a median of $44.2 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments plummeted 80.55% in 2023, then skyrocketed 1118.57% in 2024.
  • Year by year, Cash & Current Investments stood at $44.2 million in 2022, then soared by 51.03% to $66.8 million in 2023, then surged by 49.11% to $99.6 million in 2024.
  • Business Quant data shows Cash & Current Investments for ORMP at $99.6 million in Q3 2024, $86.5 million in Q2 2024, and $98.9 million in Q1 2024.